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Abstract: Endometrial cancer (EC) is the sixth most common cancer in women worldwide and
is responsible for more than 89,000 deaths every year. Mortality is associated with presence of
poor prognostic factors at diagnosis, i.e., diagnosis at an advanced stage, with a high grade and/or
an aggressive histology. Development of novel approaches that would permit us to improve
the clinical management of EC patients is an unmet need. In this study, we investigate a novel
approach to identify highly sensitive and specific biomarkers of EC using extracellular vesicles (EVs)
isolated from the peritoneal lavage of EC patients. EVs of peritoneal lavages of 25 EC patients
were isolated and their miRNA content was compared with miRNAs of EVs isolated from the
ascitic fluid of 25 control patients. Expression of the EV-associated miRNAs was measured using
the Taqman OpenArray technology that allowed us to detect 371 miRNAs. The analysis showed
that 114 miRNAs were significantly dysregulated in EC patients, among which eight miRNAs,
miRNA-383-5p, miRNA-10b-5p, miRNA-34c-3p, miRNA-449b-5p, miRNA-34c-5p, miRNA-200b-3p,
miRNA-2110, and miRNA-34b-3p, demonstrated a classification performance at area under the
receiver operating characteristic curve (AUC) values above 0.9. This finding opens an avenue for the
use of EV-associated miRNAs of peritoneal lavages as an untapped source of biomarkers for EC.
Keywords: endometrial cancer; uterine cancer; exosomes; biomarkers; miRNAs; ascitic fluid;
peritoneal lavage; liquid biopsy; extracellular vesicles; microRNAs
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1. Introduction
Endometrial cancer (EC) is the sixth most common cancer in women worldwide and is responsible
for more than 89,000 deaths every year [1]. EC is predominantly a disease that afflicts postmenopausal
women, occurs in women older than 50 years in more than 90% of cases, and is detected at a mean
age of 65 [2]. Approximately 10% of cases are diagnosed in premenopausal women, 5% of whom are
younger than 40 years. Mortality is associated with presence of poor prognostic factors at diagnosis, i.e.,
diagnosis at an advanced stage, with a high grade and/or an aggressive histology. Patients presenting
any of those features are at increased risk of recurrence, and, for them, therapeutic options are
limited. Although most ECs are diagnosed early, up to 10% of tumors are diagnosed at a late stage,
where the five-year survival drops to 16% compared to 95% in women diagnosed at an early stage [3].
Regarding histology, 80% of EC patients are diagnosed with an endometrioid histology with the
average 5-year survival of 75%. Nonetheless, the 20% of patients diagnosed with a non-endometrioid
histology account for 47% of EC-related deaths. Grade 3 endometrioid tumors are diagnosed in 15% of
all EC patients, although theses tumors are responsible for 27% of EC-related deaths.
The cornerstone treatment of EC is surgery, which is mostly standardized through all hospitals
with slight variations. The national comprehensive cancer network (NCCN) recommends both surgical
and pathological staging with total hysterectomy, bilateral salpingo-oophorectomy, and peritoneal
cytology. Although lymphadenectomy still remains the most reliable way of avowing downstaging
and correctly identifying patients who require adjuvant chemotherapy or radiotherapy, recent data
have questioned its role in early stage EC due to the high variability in node involvement and the
frequently associated comorbidities. Lymphadenectomy might not be performed in early stage EC
patients in some centers. Moreover, fertility-sparing surgery (FSS) in reproductive-age patients affected
by endometrial cancer has attracted attention in the last decade because the consequences of an
approach that is too radical may have a severe impact on a patient’s quality of life and psychological
well-being [4].
The new era of molecular advances has fostered biomarker research, although the identification
of useful biomarkers in liquid biopsies remains a challenge. Among all serum biomarkers, the human
epididymis protein 4 (HE4) has been one of the most investigated in EC. HE4 was found to be
sufficiently specific but poorly sensitive in patients with EC. The diagnostic performance of HE4
appears to be better than that of the cancer antigen 125 (CA125) in diagnosing EC at an early stage,
but its real value and efficacy for management of EC have not been clearly demonstrated in clinical
practice [5]. Hence, a clinical challenge in EC is the development of novel molecular approaches to
liquid biopsies that permit early diagnosis and recurrence control.
MicroRNAs (miRNAs) are small, non-coding RNA molecules of about 22 nucleotides in length [6]
that regulate gene expression at the post-transcriptional level by inhibiting protein translation
or destabilizing target transcripts via binding to the 3’-untranslated region (3’UTR), resulting in
transcriptional repression or mRNA degradation upon dicer cleavage [7]. miRNAs have been found
to play a critical role in almost every physiological process, including differentiation, proliferation,
and apoptosis. They have also been described as oncogenes or tumor suppressors in some tumors [8],
including EC [6]. Although miRNAs are detected intracellularly, they pass into the extracellular space
and can be detected in a broad variety of bodily fluids, either freely in circulation or contained in
extracellular vesicles (EVs) [9].
There are different types of EVs, and their size ranges from 20 to 200 nm. The largest vesicles, i.e.,
microvesicles, are released directly from the budding of the plasma membrane. The smallest vesicles,
i.e., exosomes, are formed within intracellular multivesicular bodies and released by their fusion with
the cellular membrane. Their function is to mediate intercellular communication, influencing the
recipient cell’s behavior. Importantly, EVs have attracted the interest of the scientific community
as a source of biomarkers, mainly because they carry a broad range of bioactive material (proteins,
metabolites, RNA, miRNA, etc.) that is well-protected by the lipid bilayer membrane of EVs, even if they
are extracted from circulating or proximal bodily fluids or frozen before any experimental study [10].
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Herein, we investigate the use of EVs isolated from the peritoneal lavage, a proximal fluid of
EC, as a source of potential EC biomarkers. The peritoneal lavage, at surgery, just before starting the
manipulation of the uterus, was used for staging purposes according to the old International Federation
of Gynecology and Obstretrics (FIGO) staging rules. In several centers, peritoneal washing is still
performed because of the prognostic information that the presence of cancer cells provides by cytologic
examination. However, this fluid has not been used for molecular analysis. In this study, we conducted
miRNA profiling of EVs isolated from the peritoneal lavages of 25 EC patients and the ascitic fluids of
25 non-cancer patients using the TaqMan OpenArray Human MicroRNA Panel. We identified the most
relevant individual miRNAs related to EC and characterized the biological and molecular landscape
of the EC milieu. The study was conceived as a proof of concept investigation to demonstrate the
feasibility of using the peritoneal lavage as a source of EV-associated miRNA biomarkers of EC.
2. Results
We analyzed the miRNA profile of EVs isolated from the ascitic fluids of 25 control patients
and the peritoneal lavages of 25 EC patients. Figure 1 illustrates the workflow that was followed in
this study.
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Cancers 2019, 11, 839 4 of 15
Table 1. Clinicopathological characteristics of patients.
Clinical Parameters Endometrial Cancer Control
Age
Median 61.4 65.5
Minimum 46 52
Maximum 78 90
Gender
Female 22 4
Male - 18
Pathology
Endometrial Cancer -
EEC 19 -
NEEC 3 -
Hepatic cirrhoses - 20
Other - 22
Clinical characteristics of the final cohort of patients included in the study after data normalization.
The differential expression analysis between cancer and control cases yielded a list of 114 miRNAs
that were significantly dysregulated (adj. p < 0.05 and abs(logFC) > = 1). Among those, 96 miRNA
were found to be downregulated and 18 miRNA were upregulated in EC patients (Table 2). To evaluate
whether these miRNAs can be used as biomarkers, we performed a predictive analysis using the
logistic modeling. Eight miRNAs demonstrated predictive performance with area under the receiver
operating characteristic curve (AUC) values above 0.90, including miRNA-383-5p, miRNA-10b-5p,
miRNA-34c-3p, miRNA-449b-5p, miRNA-34c-5p, miRNA-200b-3p, miRNA-2110, and miRNA-34b-3p
(Table 2, rows in bold; Figure 2). All eight miRNAs were significantly downregulated in EC patients
(from 3.75-fold to 12.18-fold in the log2_scale).
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Table 2. List of MicroRNA (miRNA) transcripts displaying a significant differential expression in patients with EC compared to control patients.
miRNA logFC p-Value adj.p-Value AUC AUC_95%CI_Lower AUC_95%CI_Upper Accuracy Sensitivity Specificity
hsa-miR-383-5p_478079_mir −7.56 2.86E-14 1.02E-11 0.961 0.938 0.985 0.884 0.876 0.892
hsa-miR-10b-5p_478494_mir −3.75 2.62E-11 3.10E-09 0.958 0.93 0.987 0.897 0.864 0.93
hsa-miR-34c-3p_478051_mir −10.56 9.57E-10 6.79E-08 0.948 0.925 0.97 0.843 0.893 0.794
hsa-miR-449b-5p_479528_mir −12.18 2.58E-11 3.10E-09 0.927 0.896 0.959 0.864 0.896 0.83
hsa-miR-34c-5p_478052_mir −5.97 5.60E-10 4.97E-08 0.924 0.891 0.957 0.845 0.86 0.83
hsa-miR-200b-3p_477963_mir −6.10 2.73E-06 6.91E-05 0.917 0.888 0.946 0.846 0.824 0.869
hsa-miR-2110_477971_mir −4.57 7.27E-07 2.58E-05 0.906 0.875 0.938 0.802 0.748 0.855
hsa-miR-34b-3p_478049_mir −6.73 4.17E-07 2.12E-05 0.903 0.874 0.932 0.752 0.719 0.786
hsa-miR-200c-3p_478351_mir −10.29 3.42E-09 2.02E-07 0.897 0.863 0.931 0.799 0.744 0.853
hsa-miR-150-5p_477918_mir 2.89 9.74E-06 2.26E-04 0.892 0.856 0.928 0.861 0.908 0.814
hsa-miR-1180-3p_477869_mir −4.62 9.40E-07 3.04E-05 0.89 0.854 0.926 0.791 0.738 0.844
hsa-miR-29c-5p_478005_mir −2.39 1.35E-06 3.70E-05 0.883 0.849 0.918 0.773 0.773 0.774
hsa-miR-190a-5p_478358_mir −2.51 1.42E-03 9.18E-03 0.871 0.831 0.911 0.816 0.813 0.82
hsa-miR-708-5p_478197_mir −5.51 1.19E-06 3.52E-05 0.865 0.826 0.903 0.77 0.684 0.856
hsa-miR-218-5p_477977_mir −6.70 1.27E-05 2.59E-04 0.859 0.816 0.901 0.715 0.53 0.9
hsa-miR-99a-3p_479224_mir −3.23 4.78E-05 7.78E-04 0.858 0.818 0.897 0.732 0.733 0.73
hsa-miR-196b-5p_478585_mir −6.63 5.15E-07 2.29E-05 0.85 0.805 0.894 0.766 0.624 0.908
hsa-miR-142-5p_477911_mir 8.86 1.89E-05 3.35E-04 0.849 0.808 0.889 0.748 0.898 0.599
hsa-miR-193a-3p_478306_mir −2.49 1.31E-03 8.93E-03 0.849 0.807 0.891 0.789 0.853 0.725
hsa-miR-193a-5p_477954_mir −3.10 1.02E-05 2.26E-04 0.848 0.808 0.888 0.791 0.78 0.802
hsa-miR-181a-5p_477857_mir −1.71 1.01E-04 1.49E-03 0.847 0.807 0.887 0.755 0.831 0.678
hsa-miR-125b-5p_477885_mir −1.86 5.22E-05 8.06E-04 0.845 0.803 0.887 0.744 0.784 0.704
hsa-miR-429_477849_mir −3.07 2.17E-04 2.65E-03 0.843 0.797 0.89 0.792 0.817 0.767
hsa-miR-30a-3p_478273_mir −1.72 4.82E-05 7.78E-04 0.841 0.803 0.88 0.698 0.738 0.657
hsa-miR-196a-5p_478230_mir −6.80 1.89E-05 3.35E-04 0.837 0.801 0.873 0.743 0.803 0.682
hsa-miR-34b-5p_478050_mir −7.34 6.87E-07 2.58E-05 0.835 0.787 0.884 0.795 0.855 0.735
hsa-miR-769-5p_478203_mir −2.81 1.60E-03 1.01E-02 0.833 0.788 0.878 0.768 0.724 0.812
hsa-miR-20a-5p_478586_mir −1.74 2.60E-04 2.88E-03 0.832 0.789 0.875 0.727 0.738 0.716
hsa-miR-320a_478594_mir −8.30 8.68E-04 6.84E-03 0.831 0.796 0.867 0.698 0.59 0.806
hsa-miR-30d-5p_478606_mir −2.36 1.01E-02 3.59E-02 0.827 0.785 0.869 0.728 0.746 0.709
hsa-miR-409-3p_478084_mir 3.24 2.24E-04 2.65E-03 0.822 0.777 0.868 0.779 0.872 0.687
hsa-miR-30b-5p_478007_mir −2.57 1.65E-03 1.01E-02 0.82 0.777 0.863 0.714 0.736 0.693
hsa-miR-598-3p_478172_mir −1.84 3.68E-04 3.53E-03 0.82 0.778 0.861 0.723 0.677 0.77
hsa-miR-369-3p_478067_mir 4.94 1.32E-04 1.81E-03 0.816 0.772 0.86 0.709 0.895 0.523
hsa-miR-187-3p_477941_mir −6.40 1.10E-04 1.56E-03 0.815 0.768 0.861 0.749 0.638 0.86
hsa-miR-210-3p_477970_mir −1.85 1.37E-04 1.81E-03 0.813 0.768 0.859 0.699 0.713 0.686
hsa-miR-29c-3p_479229_mir −2.84 1.63E-03 1.01E-02 0.812 0.773 0.851 0.742 0.749 0.735
hsa-miR-885-5p_478207_mir −3.98 3.50E-04 3.45E-03 0.812 0.768 0.857 0.713 0.741 0.686
hsa-miR-142-3p_477910_mir 3.77 2.85E-04 2.98E-03 0.81 0.764 0.857 0.71 0.775 0.645
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Table 2. Cont.
miRNA logFC p-Value adj.p-Value AUC AUC_95%CI_Lower AUC_95%CI_Upper Accuracy Sensitivity Specificity
hsa-miR-342-3p_478043_mir 2.17 5.34E-03 2.44E-02 0.808 0.763 0.854 0.721 0.739 0.703
hsa-miR-17-3p_477932_mir −6.78 2.76E-04 2.97E-03 0.806 0.762 0.85 0.739 0.826 0.652
hsa-miR-92a-3p_477827_mir −1.49 5.35E-04 4.87E-03 0.805 0.763 0.848 0.711 0.796 0.626
hsa-miR-29a-5p_478002_mir −6.21 2.46E-03 1.34E-02 0.803 0.762 0.843 0.681 0.802 0.561
hsa-miR-30e-3p_478388_mir −4.45 6.43E-03 2.78E-02 0.796 0.749 0.844 0.633 0.426 0.839
hsa-miR-125a-5p_477884_mir −1.39 1.17E-03 8.33E-03 0.794 0.749 0.839 0.746 0.768 0.723
hsa-miR-130a-3p_477851_mir −1.76 4.73E-04 4.42E-03 0.793 0.744 0.842 0.723 0.836 0.61
hsa-miR-485-3p_478125_mir 2.34 6.14E-03 2.72E-02 0.793 0.746 0.841 0.694 0.692 0.698
hsa-miR-223-3p_477983_mir 1.80 6.62E-04 5.73E-03 0.79 0.744 0.837 0.714 0.756 0.672
hsa-miR-21-5p_477975_mir 1.63 7.79E-04 6.55E-03 0.787 0.738 0.836 0.714 0.706 0.721
hsa-miR-194-5p_477956_mir −1.29 7.80E-03 3.18E-02 0.785 0.735 0.835 0.749 0.746 0.752
hsa-miR-29a-3p_478587_mir −2.40 8.07E-03 3.22E-02 0.784 0.736 0.833 0.663 0.746 0.581
hsa-miR-887-3p_479189_mir −5.02 2.54E-04 2.88E-03 0.784 0.736 0.832 0.652 0.46 0.843
hsa-miR-135a-5p_478581_mir −5.63 7.93E-04 6.55E-03 0.775 0.727 0.823 0.698 0.663 0.732
hsa-miR-31-5p_478015_mir −2.16 8.14E-04 6.56E-03 0.775 0.727 0.823 0.671 0.769 0.573
hsa-miR-29b-2-5p_478003_mir −2.82 8.96E-04 6.92E-03 0.773 0.723 0.824 0.671 0.688 0.654
hsa-miR-26b-5p_478418_mir −1.47 1.01E-03 7.45E-03 0.771 0.722 0.82 0.669 0.822 0.516
hsa-miR-656-3p_479137_mir 4.06 1.73E-03 1.04E-02 0.771 0.72 0.822 0.693 0.7 0.686
hsa-miR-33b-5p_478479_mir −4.09 1.48E-02 4.82E-02 0.767 0.718 0.816 0.64 0.591 0.69
hsa-miR-141-3p_478501_mir −8.97 1.31E-05 2.59E-04 0.765 0.715 0.815 0.718 0.847 0.589
hsa-miR-423-3p_478327_mir −1.80 3.02E-04 3.07E-03 0.765 0.714 0.816 0.679 0.67 0.687
hsa-miR-28-3p_477999_mir −2.33 2.24E-03 1.28E-02 0.764 0.714 0.813 0.658 0.621 0.695
hsa-miR-29b-3p_478369_mir −2.44 6.09E-04 5.40E-03 0.761 0.715 0.808 0.684 0.63 0.737
hsa-let-7b-5p_478576_mir −1.43 1.22E-03 8.51E-03 0.76 0.715 0.806 0.624 0.648 0.6
hsa-miR-551b-3p_478159_mir −4.13 2.14E-03 1.25E-02 0.76 0.711 0.809 0.671 0.751 0.591
hsa-miR-154-3p_478725_mir 3.28 2.78E-03 1.47E-02 0.759 0.704 0.814 0.673 0.738 0.608
hsa-miR-18a-3p_477944_mir −2.84 7.96E-03 3.21E-02 0.759 0.707 0.81 0.67 0.696 0.644
hsa-miR-26a-5p_477995_mir −1.33 6.71E-03 2.87E-02 0.759 0.709 0.809 0.685 0.622 0.748
hsa-miR-181d-5p_479517_mir −5.43 4.75E-03 2.31E-02 0.757 0.709 0.805 0.654 0.524 0.784
hsa-miR-151a-3p_477919_mir −1.65 1.05E-03 7.59E-03 0.756 0.701 0.811 0.731 0.794 0.667
hsa-miR-449a_478561_mir −5.77 2.18E-04 2.65E-03 0.755 0.701 0.808 0.712 0.812 0.611
hsa-miR-219a-5p_477980_mir −3.58 2.31E-03 1.30E-02 0.752 0.704 0.8 0.686 0.708 0.664
hsa-miR-584-5p_478167_mir −5.62 2.55E-03 1.37E-02 0.752 0.703 0.801 0.662 0.778 0.545
hsa-miR-20b-5p_477804_mir −4.91 3.96E-03 2.04E-02 0.747 0.698 0.796 0.674 0.784 0.563
hsa-miR-24-3p_477992_mir −1.30 5.35E-03 2.44E-02 0.747 0.696 0.798 0.665 0.688 0.642
hsa-miR-33a-5p_478347_mir −3.72 2.83E-03 1.48E-02 0.742 0.689 0.795 0.672 0.586 0.757
hsa-let-7e-5p_478579_mir −6.66 4.07E-03 2.06E-02 0.741 0.685 0.797 0.709 0.794 0.623
hsa-miR-543_478155_mir 2.69 1.40E-03 9.18E-03 0.741 0.687 0.795 0.685 0.544 0.826
hsa-miR-126-5p_477888_mir 5.31 1.01E-03 7.45E-03 0.74 0.686 0.795 0.723 0.826 0.62
hsa-miR-139-5p_478312_mir −3.63 5.34E-03 2.44E-02 0.738 0.69 0.787 0.641 0.433 0.849
hsa-miR-652-3p_478189_mir −1.13 1.11E-02 3.75E-02 0.737 0.687 0.786 0.613 0.621 0.605
hsa-miR-200a-3p_478490_mir −4.89 6.25E-03 2.74E-02 0.735 0.682 0.788 0.709 0.79 0.629
hsa-miR-21-3p_477973_mir 2.34 8.87E-03 3.42E-02 0.735 0.679 0.791 0.689 0.738 0.641
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Table 2. Cont.
miRNA logFC p-Value adj.p-Value AUC AUC_95%CI_Lower AUC_95%CI_Upper Accuracy Sensitivity Specificity
hsa-miR-181c-5p_477934_mir −1.86 1.08E-02 3.73E-02 0.734 0.68 0.789 0.678 0.659 0.698
hsa-miR-361-5p_478056_mir −1.20 4.86E-03 2.31E-02 0.727 0.677 0.777 0.688 0.75 0.626
hsa-miR-296-5p_477836_mir −4.15 4.87E-03 2.31E-02 0.726 0.673 0.778 0.631 0.536 0.726
hsa-miR-1271-5p_478674_mir −4.54 1.01E-02 3.59E-02 0.725 0.674 0.776 0.643 0.783 0.502
hsa-miR-125b-2-3p_478666_mir −3.58 9.83E-03 3.58E-02 0.724 0.672 0.776 0.637 0.761 0.514
hsa-miR-130b-3p_477840_mir −4.14 4.77E-03 2.31E-02 0.723 0.673 0.774 0.684 0.66 0.707
hsa-miR-545-3p_479002_mir −3.15 1.06E-02 3.69E-02 0.723 0.67 0.775 0.648 0.526 0.77
hsa-miR-331-3p_478323_mir −5.14 7.33E-03 3.10E-02 0.722 0.669 0.775 0.673 0.753 0.594
hsa-miR-128-3p_477892_mir −1.40 2.39E-03 1.33E-02 0.72 0.667 0.772 0.642 0.647 0.638
hsa-miR-148b-3p_477824_mir −1.40 7.60E-03 3.17E-02 0.72 0.662 0.778 0.663 0.746 0.58
hsa-miR-30a-5p_479448_mir −5.80 1.43E-02 4.70E-02 0.716 0.658 0.774 0.654 0.716 0.592
hsa-miR-222-3p_477982_mir −1.46 1.25E-02 4.20E-02 0.712 0.655 0.77 0.653 0.645 0.661
hsa-miR-451a_478107_mir −4.53 1.40E-03 9.18E-03 0.711 0.654 0.768 0.61 0.613 0.606
hsa-miR-203a-3p_478316_mir −4.92 9.36E-03 3.50E-02 0.708 0.653 0.764 0.664 0.804 0.524
hsa-miR-758-3p_479166_mir 3.56 9.37E-03 3.50E-02 0.705 0.653 0.756 0.652 0.692 0.612
hsa-miR-452-5p_478109_mir −2.16 1.11E-02 3.75E-02 0.703 0.644 0.762 0.598 0.571 0.626
hsa-miR-505-3p_478145_mir −1.91 6.03E-03 2.71E-02 0.703 0.647 0.759 0.604 0.553 0.655
hsa-miR-504-5p_478144_mir −2.25 1.06E-02 3.69E-02 0.701 0.647 0.756 0.624 0.58 0.667
hsa-miR-182-5p_477935_mir −5.24 9.84E-03 3.58E-02 0.7 0.639 0.761 0.686 0.683 0.688
hsa-miR-551a_478158_mir −4.09 1.58E-02 4.93E-02 0.7 0.644 0.756 0.639 0.772 0.507
hsa-miR-101-3p_477863_mir −2.79 4.16E-03 2.08E-02 0.699 0.645 0.752 0.626 0.417 0.835
hsa-miR-31-3p_478012_mir −3.59 8.29E-03 3.27E-02 0.699 0.647 0.751 0.675 0.718 0.632
hsa-miR-140-3p_477908_mir −2.87 1.56E-02 4.90E-02 0.697 0.642 0.753 0.622 0.439 0.805
hsa-miR-214-5p_478768_mir −3.30 8.46E-03 3.30E-02 0.696 0.641 0.751 0.649 0.707 0.591
hsa-miR-199b-5p_478486_mir −4.83 1.49E-02 4.82E-02 0.695 0.646 0.744 0.623 0.631 0.614
hsa-miR-337-5p_478036_mir 3.17 1.27E-02 4.22E-02 0.688 0.631 0.745 0.711 0.9 0.523
hsa-miR-154-5p_477925_mir 2.07 9.88E-03 3.58E-02 0.687 0.631 0.742 0.657 0.773 0.541
hsa-miR-582-5p_478166_mir −3.50 1.52E-02 4.83E-02 0.681 0.618 0.743 0.644 0.702 0.587
hsa-miR-126-3p_477887_mir 5.32 1.82E-03 1.08E-02 0.678 0.616 0.739 0.738 0.832 0.643
hsa-miR-143-3p_477912_mir −1.54 9.06E-03 3.46E-02 0.674 0.616 0.731 0.677 0.745 0.608
hsa-miR-324-5p_478024_mir −1.34 1.52E-02 4.83E-02 0.651 0.588 0.714 0.572 0.603 0.542
hsa-miR-145-5p_477916_mir −1.70 7.80E-03 3.18E-02 0.649 0.591 0.708 0.646 0.723 0.57
Log fold-change expression, p-value, adjusted p-value, area under the receiver operating characteristic curve (AUC) values, accuracy, sensitivity, specificity, and 95% confidence intervals of
the 114 dysregulated miRNAs.
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Figure 3. Gene Ontology (GO) analysis of the predicted proteins regulated by miRNA from EVs
of EC and control patients: (A) Biological process GO analysis of predicted proteins regulated by
differentially expressed miRNA from the ELV of EC and control patients. A total of 8074 genes were
predicted to be modulated by 114 miRNA and were included in at least one of the GO Biological
process categories as indicated in the pie chart. Others include the following categories that have
less than 0.4% of representation: growth; multi-organism process; biological phase; rhythmic process;
pigmentation; nitrogen utilization. (B) Molecular Function GO analysis of predicted proteins regulated
by differentially expressed miRNA from the ELV of EC and control patients. A total of 8074 genes
were predicted to be modulated by 115 miRNA and were included in at least one of the GO Molecular
Function categories as indicated in the pie chart. Abbreviations: Reg, Regulation; Pr, Process; Bd,
Binding; Act, Activity.
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3. Discussion
In this study, we investigated for the first time the miRNA content of EVs isolated from peritoneal
lavages and ascitic fluids of EC and control patients, respectively. Our study shows that the
EV-associated miRNAs can be consistently extracted from those proximal bodily fluids and that
the miRNA expression profiles can indicate and represent the status of EC patients. The EV-associated
miRNAs were analyzed using the Taqman OpenArray technology. The differential expression analysis
yielded 114 miRNAs that were significantly dysregulated in EC patients.
An abundance of scientific research has been published regarding the role of miRNAs in EC [11].
Torres et al. published the first study focused on miRNA expression both in tissue and plasma samples
of EC patients. They investigated the expression of miRNA-99a, miRNA-100, and miRNA-199b,
which target the mTOR kinase. A combined signature of miRNA-99a and miRNA-199b in plasma
samples resulted in 88% sensitivity and 93% specificity, indicating a good diagnostic potential [12].
Despite these findings, they were not applied in the clinical setting [13]. In this respect, EVs arise as
a source of biomarkers with an unexploited potential. They can be isolated from bodily fluids, such as
saliva, blood, urine, malignant pleural effusion, and ascitis [14]. In EC, miRNAs isolated from EVs have
been scarcely studied. Akhil et al. evaluated the potential of the miRNA content of urine-derived EVs
as a diagnostic biomarker in EC patients [15], and Hanzi Xu et al. isolated EVs from serum samples
and identified 209 upregulated and 66 downregulated circular RNA (circRNAs) in EVs from serum of
patients with EC compared with those from serum of healthy controls [16].
Although plasma, serum, and urine biopsies are the most common liquid biopsies, the use of
proximal bodily fluids as a source of biomarkers has attracted the attention of the biomarker research
community. Proximal bodily fluids, such as uterine fluid for EC, offer an improved representation of
the molecular alterations that take place in the tumor [17]. The peritoneal fluid is another proximal
fluid of EC; however, this type of proximal fluid has not been yet exploited to investigate EC-related
biomarkers or any other cancer originating within the peritoneal cavity.
To the best of our knowledge, our study is the first to report the value of this proximal fluid
for the identification of miRNAs associated with EVs in EC. Importantly, this study identified
the dysregulation of 114 miRNAs, among which miRNA-383-5p, miRNA-10b-5p, miRNA-34c-3p,
miRNA-449b-5p, miRNA-34c-5p, miRNA-200b-3p, miRNA-2110, and miRNA-34b-3p are of special
interest, as they demonstrated a high classification potential. Interestingly, some of these miRNAs
were found in previous EC studies. In concordance with our study, miRNA-10b and miRNA-34b were
found to be downregulated in endometrial serous adenocarcinoma versus normal endometrial tissue,
indicating that these miRNAs might also be associated with the aggressive subtype of the serous EC.
In fact, in that study, reduced miRNA-10b expression was found to be significantly correlated with
shorter overall survival [18]. MiRNA-34 has been described as a fundamental regulator of tumor
suppression; it controls multiple protein targets involved in the cell cycle and apoptosis, and was
associated with metastasis and chemoresistance [19]. In contrast to our study, miRNA-200b was
found to be upregulated in endometrial serous adenocarcinoma versus normal endometrial tissue [18].
However, it has been reported to be downregulated in various human malignancies, and its function
has been postulated to be oncogenic (i.e., involved in proliferation, motility, apoptosis, stemness,
and the epithelial-to-mesenchymal transition) [20]. Interestingly, accumulating evidence in the field of
endometriosis suggests that apoptosis that occurs in the peritoneal cavity may play a pivotal role in
addressing the immune homeostasis in the peritoneal microenvironment [21]. This causes scavenging
mechanisms to fail, allowing for the survival of endometriotic cells in patients with endometriosis [22].
In the context of endometrial cancer, we speculate that EVs derived from endometrial cancer cells
might reach the peritoneal cavity and target the mesothelial liner cells of the peritoneum and ovaries to
modulate the immune homeostasis and create a more favorable milieu to metastasize. In fact, most of
the metastasis associated with endometrial cancer occurs either in the vagina, in the lymph nodes,
or within the peritoneal cavity. Several of the miRNAs identified in our study are related to tumor
progression in endometrial cancer or in other tumor types. It is possible that endometrial cancer cells
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may spread into the peritoneum and the ovaries through the Fallopian tube, and develop peritoneal
metastasis and ovarian metastasis in the absence of lympho-vascular space invasion. It is important to
note that normal endometrium may spread into the peritoneum and the ovaries through retrograde
menstruation, and give rise to endometriosis. Metastasis that originates through this pathway may be
associated with indolent behavior. A subset of ECs from ovarian metastasis are associated with such
a good prognosis that they were interpreted as synchronous tumors [23]. Next-generation sequence
analysis has confirmed that they are metastatic. Assessing transtubal exosomal release from endometrial
cancer may help us to understand the mechanisms involved in this type of indolent metastasis.
The study leaves some questions open. This study enabled us to identify a large number of
dysregulated miRNAs associated with EVs in the peritoneal lavage of EC patients. We think that the
EVs that we have identified come from endometrial and mesothelial cells in the EC group, and mostly
from mesothelial cells in the control group. The comparative analysis of EC patients with non-cancer
patients with ascites suggests that these selected miRNAs come from EVs of EC tissue. However, there is
obviously the probability that a subset of EVs came from an inflammatory reaction associated with EC
and some other factors distinct from the EC pathology, such as the source of EVs (peritoneal lavage vs.
ascitic fluids), the surgery (after induction of general anesthesia), and the control samples, which were
obtained by means of paracentesis (with local anesthesia). Nevertheless, these promising biomarkers
should be further validated as well as combined in order to increase the already excellent accuracy of
each individual miRNA. This should be done in an independent study involving a larger cohort of
EC patients versus a control group with a higher biologic variability, including, for example, patients
with leiomyomas or women requiring tubal ligation for definitive contraception. Although we tested
whether or not differentially expressed miRNAs were dependent on gender, further studies should
include only female controls. Moreover, further research should be directed to an evaluation of the
prognostic potential of each specific dysregulated miRNA, as this might help to guide the surgical
treatment of EC patients.
4. Materials and Methods
4.1. Patients and Ascitic Fluid and Peritoneal Lavage Collection
All subjects provided informed consent before they participated in the study. The study was
conducted in accordance with the Declaration of Helsinki, and the protocol was approved by
The Clinical Research Ethics Committee of Hospital Arnau de Vilanova in Lleida, Spain (Approval
number: CEIC-1630). Samples were obtained with support from the IRBLleida Biobank (B.0000682)
and Plataforma biobancos PT17/0015/0027. Ascitic fluids and peritoneal lavages were extracted
from a cohort of 50 patients, corresponding to 25 control patients with decompensated cirrhosis and
25 patients with EC who underwent curative surgery. In the control patients, the collection of ascitic
fluids was performed as follows: Ascitic fluids were aspirated using 18 or 21G needles (for diagnostic
paracentesis) or an over-the-needle catheter device (for therapeutic paracentesis). The procedure was
performed under sterile conditions, the needle insertion site was selected by ultrasound guidance,
and the skin and parietal peritoneum were previously anesthetized with 2% mepivacine. A total
of 100 mL of ascitic fluid was gently aspirated, collected into a 50 mL tube, and stored at −80 ◦C
until use. In EC patients, the collection of peritoneal lavage was performed during surgery, once
the abdominal cavity was opened and prior to any manipulation of the uterus. A total of 100 mL of
physiological saline was instilled into the abdominal cavity with a 50 mL syringe, mobilizing patients
for the correct distribution of saline, which was then extracted with a 50 mL syringe connected to
a 14-gauge aspiration needle. The peritoneal lavage was gently aspirated. A volume ranging from
50 to 100 mL was collected and stored at −80 ◦C until use. The clinical features of each patient are
listed in Supplementary Table S1.
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4.2. EV Isolation
EVs were isolated with a differential centrifugation method as previously described [24] with
slight modifications. Briefly, ascitic fluids and peritoneal lavages were centrifuged at 300× g for
10 min, followed by centrifugation at 2500× g for 20 min at the moment that the sample was collected,
and frozen at −80 ◦C. Then, samples were centrifuged at 10,000 g for 30 min (Thermo Scientific
Heraeus MultifugeX3R Centrifuge (FiberLite rotor F15-8x-50c)). The supernatant was filtered through
0.22 µm filters (Merck Millipore), and the obtained sample was transferred to ultracentrifuge tubes
(Beckman Coulter), which were filled with phosphate-buffered saline (PBS), to perform two consecutive
ultracentrifugation steps at 100,000 g for 2 hours each on a Thermo Scientific Sorvall WX UltraSeries
Centrifuge with an AH-629 rotor. The pellet containing the EVs was resuspended in 50 µL of PBS.
From those, 5 µL were isolated for nanoparticle tracking analysis (NTA) and quantification, and the
rest was frozen at −80 ◦C with 500 µL of Qiazol for RNA extraction.
4.3. Nanoparticle Tracking Analysis
The size and number of EVs were determined using a Nanosight LM10 instrument equipped with
a 405 nm laser and a Hamamatsu C11440 ORCA-Flash 2.8 camera (Hamamatsu) with Nanoparticle
Tracking Analysis (NTA, Malvern Instruments, UK). Each sample was diluted appropriately with
Milli-Q water (Milli-Q Synthesis, Merck Millipore, MA, USA) to give counts in the linear range of the
instrument. The particles in the laser beam underwent Brownian motion, and a video was recorded for
60 s in triplicate. The analysis was performed by following the manufacturer’s instructions, and data
were analyzed using version 2.3 of the NTA software.
4.4. Total RNA Extraction and OpenArray Analysis
Total RNA, including miRNAs and other RNAs, was isolated from the EV samples using
the miRNeasy MiniKit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol.
RNA from EVs was eluted with 30 µL of Nuclease-free water (Qiagen, Hilden, Germany).
MiRNA expression was determined using a TaqMan OpenArray Human MicroRNA Panel, QuantStudio
12K Flex (Catalog number: 4470187, Thermo Fisher Scientific, Waltham, MA, USA), a fixed-content
panel containing 754 well-characterized human miRNA sequences from the Sanger miRBase v14,
and according to the manufacturer’s instructions. Reverse transcription (RT) was performed on 2 µL
RNA using Megaplex™ Primer Pools A and B and the supporting TaqMan® MicroRNA Reverse
Transcription Kit as follows: 15 min at 42 ◦C and 5 min at 85 ◦C. Then, 5 µL of the resulting cDNA
was preamplified prior to real-time PCR analysis using Megaplex™ PreAmp Pools and the TaqMan®
PreAmp Master Mix using the following conditions: one single step at 95 ◦C for 5 min, 20 cycles of
a two-step program (3 sec, 95 ◦C and 30 sec, 60 ◦C) followed by a single cycle of 10 min at 99 ◦C
to inactivate the enzyme. The preamplified products were diluted to 1:20 in 0.1× TE buffer pH 8.0,
and mixed in a 1:1 ratio with TaqMan® OpenArray® Real-Time PCR Master Mix in the 384-well
OpenArray® Sample Loading Plate. TaqMan® OpenArray® MicroRNA Panels were automatically
loaded using the AccuFill™ System.
4.5. Preprocessing and Differential Expression Analysis
All bioinformatics analyses were performed with BioConductor (version 3.7) [25] in the R
statistical environment (version 3.5.0) [26]. For the data preprocessing, the HTqPCR (version 1.34)
R package [27] was used. Probes that had a “Cycle threshold” (Ct) value of 40 in all samples were
removed. Samples in which more than 80% of the probes had a Ct value greater than 40 were retained.
To assure comparability across samples, the Ct values were delta-normalized. The average Ct values
of the probes hsa−miR−150−5p, hsa−let−7g-5p, hsa−miR−598−3p, and hsa−miR−361−3p were used
for normalization. These probes had Ct values of 40 in a maximum of three samples and the lowest
interquartile range across all samples. The differential expression analysis was carried out with the
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empirical Bayes approach on linear models using the limma (version 3.36) R Package [28]. Results were
corrected for multiple testing using the False Discovery Rate (FDR) [29].
4.6. Development of Predictors
For predictive analysis, the whole patient cohort was randomly divided into training and validation
sets with a ratio of 3:2. Calculated (with the limma R Package) relative miRNA expression values
were used as input variables into a logistic regression model between groups. Each miRNA (adjusted
p-value <0.05) was fitted in the logistic regression model to differentiate the EC and the control patient
groups in the training set, and its classification ability was evaluated using the area under the ROC
curve (AUC), accuracy, sensitivity, and specificity values on the validation set. The procedures for
the division of the patient cohort into training and validation sets and fitting the logistic model were
repeated 500 times and statistics were collected.
4.7. miRNA Target Gene Prediction and Bioinformatics Analysis
miRNA target genes were predicted using the Predictive Target Module of the miRWalk2.0 online
software [30] (https://goo.gl/ajG9ja). Only genes for which miRNAs recognize a minimum 7 bp seed
length, seed start at position 1, and sequence localize at 3´UTR were considered as valid targets.
Moreover, to improve target gene prediction accuracy, we considered only those transcripts that were
predicted in at least eight out of the 12 databases (miRWalk, miRanda, MicroT4, miRDB, miRMap,
miRBridge, miRNAMap, PICTAR2, RNA22, PITA, TargetScan, and RNAhybrid) presented in the
miRWalk2.0 tool.
The online Panther software [31] (http://www.pantherdb.org/) was used for the Gene Ontology (GO)
functional analysis to analyze the potential functions of the predicted target genes. Biological process
(BP) and molecular function (MF) GO terms were analyzed and plotted.
5. Conclusions
Thanks to this study, we have demonstrated that the use of EV-associated miRNAs of ascitic
fluid from control patients and peritoneal lavages from EC patients are an untapped source of
biomarkers. Specifically, we identified 114 dysregulated miRNAs, and, among those, miRNA-383-5p,
miRNA-10b-5p, miRNA-34c-3p, miRNA-449b-5p, miRNA-34c-5p, miRNA-200b-3p, miRNA-2110, and
miRNA-34b-3p were highlighted as promising biomarkers of EC with an AUC value higher than 0.90.
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